Stonegate Capital Partners has updated its coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage CNS oncology company focused on developing therapies designed to overcome the blood-brain barrier (BBB) and improve drug delivery to the brain. The company's lead program, NEO212, is a next-generation version of temozolomide (TMZ), the standard-of-care chemotherapy used in most brain cancer patients. NEO212 is designed to address key limitations of current treatment, including BBB penetration and MGMT-driven resistance.
Beyond its lead programs, NeOnc’s platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. The company recently led a successful PIPE offering, adding a gross $16.0M to its balance sheet. Key takeaways from the update include NEO212's progress: a Phase 1 dose escalation in recurrent glioblastoma (GBM) has completed with a Recommended Phase 2 Dose of 610 mg established and early signs of disease control observed, positioning the program to advance into Phase 2 efficacy evaluation.
Additionally, NEO100 is a non-invasive intranasal therapy targeting recurrent GBM, with Phase 2 data showing radiographic responses and improved progression-free survival versus historical salvage benchmarks. For more details, the full announcement is available here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.
This update underscores NeOnc's potential to address significant unmet needs in brain cancer treatment, particularly in overcoming drug resistance and improving delivery across the BBB. The successful financing also strengthens the company's ability to advance its clinical programs.
